ArticleBMC cancer2018

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).

Florian Huemer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.